We found many signaling pathways common to both, such as the P13-AKT-signaling-pathway and MAPK-signal-pathway, suggesting that the GPR-TME-score may influence the response to immunotherapy in BLCA patients through the above pathways (Figure 5j). This evidence concerns the gene AKT1 and bladder transitional cell carcinoma.